VistaGen can’t puff out phase 3 success for social anxiety nasal spray

The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes just got even higher, after the results of the first of the two found that the company swung and missed.